Cefepime vs Cefaclor — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Cephalosporin Antibacterial

Cefepime

Brand: CEFEPIME HYDROCHLORIDE AND DEXTROSE

First FDA approval: 2008-05-01

Cephalosporin Antibacterial

Cefaclor

First FDA approval: 2002-09-26

Lowest NADACAcquisition cost floor across all NDCs

$3.73Per unit

$0.874Per unit

Average NADACAcross all dosage forms and strengths

$3.73Up to $3.73

$1.06Up to $1.26

Generic manufacturersActive ANDA holders — FDA Orange Book

510 total ANDAs filed

28 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$27.5MFull year

$825749Full year

Part D claims (CY24)Total fills, all strengths

150K51K beneficiaries

14K8K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$183Per claim, all NDCs

$60Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes5 manufacturers

Yes2 manufacturers